Investigational drugs for the treatment of dysmenorrhea.

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-19 DOI:10.1080/13543784.2024.2326627

Amelia K Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour

{"title":"Investigational drugs for the treatment of dysmenorrhea.","authors":"Amelia K Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour","doi":"10.1080/13543784.2024.2326627","DOIUrl":null,"url":null,"abstract":"Introduction: Dysmenorrhea is the most common cause of gynecological pain among women that has considerable impact on quality of life and psychosocial wellbeing. Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies are most commonly used to treat dysmenorrhea. However, given these drugs are often associated with bothersome side effects and are less effective when there is an underlying cause contributing to dysmenorrhea (e.g. endometriosis), a patient-centered approach to managing dysmenorrhea is important. Various new drugs are currently being investigated for the treatment of primary and secondary dysmenorrhea.Areas covered: This review provides an updated overview on new therapeutic targets and investigational drugs for the treatment of primary and secondary dysmenorrhea. The authors describe the clinical development and implications of these drugs.Expert opinion: Among the investigative drugs discussed in this review, anti-inflammatories show the most promising results for the treatment of dysmenorrhea. However, given some trials have considerable methodological limitations, many drugs cannot be currently recommended. Research focused on understanding the mechanisms involved in menstruation and its associated symptoms will be important to identify new therapeutic targets for dysmenorrhea. Further robust clinical trials are required to better understand the efficacy and safety of investigational drugs for treating primary and secondary dysmenorrhea.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2024.2326627","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Dysmenorrhea is the most common cause of gynecological pain among women that has considerable impact on quality of life and psychosocial wellbeing. Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies are most commonly used to treat dysmenorrhea. However, given these drugs are often associated with bothersome side effects and are less effective when there is an underlying cause contributing to dysmenorrhea (e.g. endometriosis), a patient-centered approach to managing dysmenorrhea is important. Various new drugs are currently being investigated for the treatment of primary and secondary dysmenorrhea.

Areas covered: This review provides an updated overview on new therapeutic targets and investigational drugs for the treatment of primary and secondary dysmenorrhea. The authors describe the clinical development and implications of these drugs.

Expert opinion: Among the investigative drugs discussed in this review, anti-inflammatories show the most promising results for the treatment of dysmenorrhea. However, given some trials have considerable methodological limitations, many drugs cannot be currently recommended. Research focused on understanding the mechanisms involved in menstruation and its associated symptoms will be important to identify new therapeutic targets for dysmenorrhea. Further robust clinical trials are required to better understand the efficacy and safety of investigational drugs for treating primary and secondary dysmenorrhea.

查看原文本刊更多论文

治疗痛经的研究药物。

简介痛经是女性最常见的妇科疼痛原因，对生活质量和社会心理健康有很大影响。非甾体抗炎药（NSAIDs）和激素疗法是治疗痛经最常用的方法。然而，鉴于这些药物通常会产生令人烦恼的副作用，而且当痛经的根本原因（如子宫内膜异位症）存在时，这些药物的疗效就会大打折扣，因此，以患者为中心的痛经治疗方法非常重要。目前正在研究用于治疗原发性和继发性痛经的各种新药：本综述概述了治疗原发性和继发性痛经的新治疗靶点和在研药物的最新情况。作者介绍了这些药物的临床开发和影响：专家观点：在本综述讨论的研究药物中，抗炎药在治疗痛经方面显示出最有希望的结果。然而，由于试验在方法上存在相当大的局限性，这些药物目前还不能付诸实施。研究重点在于了解月经及其相关症状的发病机制，这对于确定治疗痛经的新靶点非常重要。要更好地了解治疗原发性和继发性痛经的研究药物的疗效和安全性，还需要进一步开展强有力的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.